Atypical Antipsychotics:
The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hal...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Basel
Birkhäuser Basel
2000
|
| Schriftenreihe: | Milestones in Drug Therapy
|
| Schlagworte: | |
| Online-Zugang: | UBR01 URL des Erstveröffentlichers |
| Zusammenfassung: | The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hallu cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro longed treatment, represented a major problem in the treatment of schizo phrenic patients |
| Beschreibung: | 1 Online-Ressource (XI, 236 p) |
| ISBN: | 9783034884488 |
| DOI: | 10.1007/978-3-0348-8448-8 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046149232 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190906s2000 |||| o||u| ||||||eng d | ||
| 020 | |a 9783034884488 |9 978-3-0348-8448-8 | ||
| 024 | 7 | |a 10.1007/978-3-0348-8448-8 |2 doi | |
| 035 | |a (ZDB-2-SBL)978-3-0348-8448-8 | ||
| 035 | |a (OCoLC)1118996903 | ||
| 035 | |a (DE-599)BVBBV046149232 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.89 |2 23 | |
| 084 | |a XI 5800 |0 (DE-625)153018:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Atypical Antipsychotics |c edited by Bart A. Ellenbroek, Alexander R. Cools |
| 264 | 1 | |a Basel |b Birkhäuser Basel |c 2000 | |
| 300 | |a 1 Online-Ressource (XI, 236 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Milestones in Drug Therapy | |
| 520 | |a The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hallu cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro longed treatment, represented a major problem in the treatment of schizo phrenic patients | ||
| 650 | 4 | |a Psychiatry | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Psychiatry | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Neurology | |
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Psychopharmakon |0 (DE-588)4047729-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Psychopharmakon |0 (DE-588)4047729-0 |D s |
| 689 | 0 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Ellenbroek, Bart A. |4 edt | |
| 700 | 1 | |a Cools, Alexander R. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034895712 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783764359485 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034884495 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-0348-8448-8 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 940 | 1 | |q ZDB-2-SBL_2000/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031529409 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-0348-8448-8 |l UBR01 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180490587996160 |
|---|---|
| any_adam_object | |
| author2 | Ellenbroek, Bart A. Cools, Alexander R. |
| author2_role | edt edt |
| author2_variant | b a e ba bae a r c ar arc |
| author_facet | Ellenbroek, Bart A. Cools, Alexander R. |
| building | Verbundindex |
| bvnumber | BV046149232 |
| classification_rvk | XI 5800 |
| collection | ZDB-2-SBL |
| ctrlnum | (ZDB-2-SBL)978-3-0348-8448-8 (OCoLC)1118996903 (DE-599)BVBBV046149232 |
| dewey-full | 616.89 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.89 |
| dewey-search | 616.89 |
| dewey-sort | 3616.89 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-0348-8448-8 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03271nmm a2200565zc 4500</leader><controlfield tag="001">BV046149232</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2000 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783034884488</subfield><subfield code="9">978-3-0348-8448-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-0348-8448-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-3-0348-8448-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118996903</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046149232</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.89</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5800</subfield><subfield code="0">(DE-625)153018:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Atypical Antipsychotics</subfield><subfield code="c">edited by Bart A. Ellenbroek, Alexander R. Cools</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel</subfield><subfield code="b">Birkhäuser Basel</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XI, 236 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Milestones in Drug Therapy</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hallu cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro longed treatment, represented a major problem in the treatment of schizo phrenic patients</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychiatry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychiatry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ellenbroek, Bart A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cools, Alexander R.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034895712</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783764359485</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034884495</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-0348-8448-8</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031529409</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-0348-8448-8</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046149232 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:35Z |
| institution | BVB |
| isbn | 9783034884488 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031529409 |
| oclc_num | 1118996903 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XI, 236 p) |
| psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Birkhäuser Basel |
| record_format | marc |
| series2 | Milestones in Drug Therapy |
| spelling | Atypical Antipsychotics edited by Bart A. Ellenbroek, Alexander R. Cools Basel Birkhäuser Basel 2000 1 Online-Ressource (XI, 236 p) txt rdacontent c rdamedia cr rdacarrier Milestones in Drug Therapy The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hallu cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro longed treatment, represented a major problem in the treatment of schizo phrenic patients Psychiatry Pharmacology/Toxicology Neurology Toxicology Pharmakologie (DE-588)4045687-0 gnd rswk-swf Psychopharmakon (DE-588)4047729-0 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Psychopharmakon (DE-588)4047729-0 s Pharmakologie (DE-588)4045687-0 s DE-604 Ellenbroek, Bart A. edt Cools, Alexander R. edt Erscheint auch als Druck-Ausgabe 9783034895712 Erscheint auch als Druck-Ausgabe 9783764359485 Erscheint auch als Druck-Ausgabe 9783034884495 https://doi.org/10.1007/978-3-0348-8448-8 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Atypical Antipsychotics Psychiatry Pharmacology/Toxicology Neurology Toxicology Pharmakologie (DE-588)4045687-0 gnd Psychopharmakon (DE-588)4047729-0 gnd |
| subject_GND | (DE-588)4045687-0 (DE-588)4047729-0 (DE-588)4143413-4 |
| title | Atypical Antipsychotics |
| title_auth | Atypical Antipsychotics |
| title_exact_search | Atypical Antipsychotics |
| title_full | Atypical Antipsychotics edited by Bart A. Ellenbroek, Alexander R. Cools |
| title_fullStr | Atypical Antipsychotics edited by Bart A. Ellenbroek, Alexander R. Cools |
| title_full_unstemmed | Atypical Antipsychotics edited by Bart A. Ellenbroek, Alexander R. Cools |
| title_short | Atypical Antipsychotics |
| title_sort | atypical antipsychotics |
| topic | Psychiatry Pharmacology/Toxicology Neurology Toxicology Pharmakologie (DE-588)4045687-0 gnd Psychopharmakon (DE-588)4047729-0 gnd |
| topic_facet | Psychiatry Pharmacology/Toxicology Neurology Toxicology Pharmakologie Psychopharmakon Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-0348-8448-8 |
| work_keys_str_mv | AT ellenbroekbarta atypicalantipsychotics AT coolsalexanderr atypicalantipsychotics |